OSSEKA is contraindicated: in all diseases associated with hypercalcaemia; in patients with evidence of metastatic calcification; in patients with known hypersensitivity to calcitriol (or drugs of the same class) and any of the constituent excipients; if there is evidence of vitamin D toxicity.